|Generate QR code
Open Access
Subscription Access
SIMULTANEOUS DETERMINATION AND VALIDATION OF ANTI-TUBERCULAR DRUGS IN SIMULATED LUNGS ALVEOLAR MACROPHAGES FLUID BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRIC METHOD
Abstract
An ultraviolet-visible (UV-Vis) spectrophotometric method was developed for the simultaneous determination of isoniazid (INH) and rifampicin (RIF) using Vierordt’s method. In this method, along with methanol, two other solvents such as phosphate buffer pH 7.4 and citro-phosphate buffer pH 5.0 were also selected, the former of which is simulated with the pH of lung epithelial lining fluid and the latter is simulated with the phagolysosomal environment. A 1:1.5 ratio of pure INH:RIF was selected and scanned, which showed similar absorption maxima at three solvents, and on that basis absorption maxima at 263 and 335 nm of INH and RIF, respectively, were selected. A calibration curve within the concentration ranges between 4 and 24 µg/mL of INH and 6–36 µg/mL of RIF follows the Beer–Lambert law. It was validated with respect to linearity, sensitivity, precision, and accuracy according to International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines.
Supporting agencies: The authors would like to acknowledge Chhatrapati Shahu Maharaj Research, Training and Human Development Institute (SARTHI), Pune, Maharashtra, India, for providing financial support to Vidyadevi Bhoyar through Chhatrapati Shahu Maharaj National Research Fellowship (CSMNRF2019). The authors would also like to thank Lupin Limited, Chikalthana, Aurangabad, Maharashtra, India, for providing gratis samples.
About the Authors
V. Bhoyar
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Mahatma Jyotiba Fuley Shaikshanik Parisar
India
India
Vidyadevi Bhoyar
Nagpur
V. S. Belgamwar
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Mahatma Jyotiba Fuley Shaikshanik Parisar
India
India
Veena S. Belgamwar
Nagpur
S. Trivedi
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Mahatma Jyotiba Fuley Shaikshanik Parisar
India
India
Sagar Trivedi
Nagpur
References
1. World Health Organisation, End TB Strategy, World Health Organization, 53, 1689–1699 (2013).
2. CDC fact sheet, Tuberculosis : An Overview, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers, 2014. Assessed on 10th sept 2021 at https://www.cdc.gov/tb/publications/factsheets/general/tb.htm#:~:text=Tuberculosis%20(TB)%20is%20a%20disease,they%20do%20not%20get%20treatment.
3. S. D. A. Burke, Rev. Anthropol., 40, 27–52 (2011), doi: 10.1080/00938157.2011.547754.
4. S. M. Swain, I. C. Behera, Egypt. J. Ear, Nose, Throat Allied Sci., 18, 237–240 (2017).
5. M. Tilinca, G. Hancu, E. Mircia, D. Iriminescu, A. Rusu, R. A. Vlad, E. Barabás, Farmacia, 65, 219–224 (2017).
6. U. Shah, A. Jasani, Int. J. Pharm. Pharm. Sci., 6, 274–280 (2014).
7. Interactive Core Curriculum on Tuberculosis, Chapter 6 Treatment of Tuberculosis Disease, Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta GA 30329, USA, Assessed on 1st Sept 2021 at https://www.cdc.gov/tb/education/corecurr/pdf/chapter6.pdf
8. B. Prasanthi, J. V. Ratna, R. S. C. Phani, J. Anal. Chem., 70, 1015–1022 (2015).
9. M. A. O. Mohamed, S. W. Shantier, M. A. Mohamed, E. A. Gadkariem, E. M. O. Ismail, Int. J. Pharm. Sci. Rev. Res., 32, 154–156 (2015).
10. S. K. Arifa Begum, D. Basava Raju, N. Rama Rao, Der Pharm. Lett., 5, 419–426 (2013).
11. L. Cunha, A. M. Rosa da Costa, J. P. Lourenço, F. Buttini, A. Grenha, J. Microencapsul., 35, 392–405 (2018), doi:10.1080/02652048.2018.1513089.
12. J. B. S. A. H. Beckett, In: Pract. Pharm. Chem., pt. II, 4th Ed., ch. 7, CBS Publishers & Distributors Pvt. Ltd., 257–337 (2007).
13. The Indian Pharmacopoeia Commission, Indian Pharmacopoeia, 1, 241–243 (2007).
14. Rifampicin and Isoniazid Tablets: Revised Draft Proposal for the International Pharmacopoeia (October 2005), World health organization (2005).
15. Guidance for Industry Q2B Validation of Analytical Procedures: Methodology (1996), http://www.fda.gov/cder/guidance/index.htmorhttp://www.fda.gov/cber/guidelines.htm, accessed 20 October (2021).
Review
For citations:
Bhoyar V., Belgamwar V.S., Trivedi S. SIMULTANEOUS DETERMINATION AND VALIDATION OF ANTI-TUBERCULAR DRUGS IN SIMULATED LUNGS ALVEOLAR MACROPHAGES FLUID BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRIC METHOD. Zhurnal Prikladnoii Spektroskopii. 2022;89(5):688-693.
Views: 147
Email this article 